Literature DB >> 20522334

Management of macular edema from retinal vein occlusions: you can never have too many choices.

Neil M Bressler, Andrew P Schachat.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20522334     DOI: 10.1016/j.ophtha.2010.03.037

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


× No keyword cloud information.
  6 in total

1.  Intravitreal dexamethasone implant (Ozurdex) for macular edema secondary to retinitis pigmentosa.

Authors:  Mayer Srour; Giuseppe Querques; Nicolas Leveziel; Jennyfer Zerbib; Julien Tilleul; Elise Boulanger-Scemama; Eric H Souied
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-12-29       Impact factor: 3.117

2.  Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion.

Authors:  E Moisseiev; M Goldstein; M Waisbourd; A Barak; A Loewenstein
Journal:  Eye (Lond)       Date:  2012-11-16       Impact factor: 3.775

3.  Managing patients with retinal vein occlusions: is there any real step forward?

Authors:  S Natarajan
Journal:  Indian J Ophthalmol       Date:  2012-07       Impact factor: 1.848

4.  Retinal vein occlusion and macular edema - critical evaluation of the clinical value of ranibizumab.

Authors:  Pearse A Keane; Srinivas R Sadda
Journal:  Clin Ophthalmol       Date:  2011-06-09

5.  Aflibercept in branch retinal vein occlusion as second line therapy: clinical outcome 12 months after changing treatment from bevacizumab/ranibizumab-a pilot study.

Authors:  Magdalena A Wirth; Matthias D Becker; Nicole Graf; Stephan Michels
Journal:  Int J Retina Vitreous       Date:  2016-08-23

6.  Evaluation of the Effectiveness of Treatment with Dexamethasone Intravitreal Implant in Cystoid Macular Edema Secondary to Retinal Vein Occlusion.

Authors:  Simone Donati; Carlo Gandolfi; Simona Maria Caprani; Jennifer Cattaneo; Laura Premoli; Claudio Azzolini
Journal:  Biomed Res Int       Date:  2018-08-02       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.